Mumbai, March 4 -- According to an exchange filing, the basket of acquired ANDAs consists of 13 USFDA-approved applications and one that is pending approval.

The addressable market opportunity for these ANDAs in the U.S. is estimated at approximately USD 421 million (MAT December 2024), as per IQVIA, and around USD 1.13 billion (MAT September 2024), according to specialty data aggregator Symphony.

The acquisition will be funded through the proceeds raised from Senores Pharmaceuticals' Initial Public Offer (IPO), in line with the objectives outlined in the Red Herring Prospectus.

Swapnil Shah, Managing Director, Senores Pharmaceuticals, said, "We are glad to announce the acquisition of a basket of products from Dr. Reddy's. It spans acr...